Of the 15 trials having a cross-over design (table ?(table3)3) [1,2,3,4,5,10,30,31,32,33,34,35,36,37,38] and 31 tests having a parallel-group comparison design (table ?(table4)4) [13,16,23,26,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65], 6 [1,2,3,4,5,10] and 4 [13,16,23,26], respectively, were portion of placebo-controlled studies – Structure-Based Design of mTORC1 Inhibitors in Cancer Therapy